HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.
QIAsphere sets new standards for syndromic testing digital health, providing users with remote visibility of their testing routine. It can monitor a nearly unlimited number of instruments, providing visibility of testing routine across different hospitals or satellite labs. The continuous connectivity to QIAGEN service reduces systems downtime and enabling fast and accurate syndromic testing. Digital diagnostics and remote analytics will be crucial to bring syndromic testing closer to patients in the coming years.
Customers using QIAsphere will be able to remotely monitor their QIAstat-Dx instrument and test status, received push notifications across their personal devices, such as smartphones, desktop PCs and smartwatches.
QIAstat-Dx connectivity with QIAsphere will also allow QIAGEN technical service to monitor customers instruments health in real-time, whilst providing them with rapid response to minimized systems downtime.
QIAGEN began marketing and distributing QIAsphere for the QIAcube Connect platform in early 2021 and will expand its scope into Molecular Diagnostics with its syndromic testing platform QIAstat-Dx. QIAGEN plans to extend the scope of QIAsphere across many platforms and solutions in the coming months.
“The launch of QIAsphere platform for QIAstat-Dx is a key step in syndromic testing, but above all for our customers: it is our commitment to make their life easier, their testing workflow more manageable and our interactions faster,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. “Digital diagnostics sets a new paradigm in syndromic testing. It addresses the growing need of bringing molecular PCR COVID testing closer to patients and to decentralized environments such as ICUs, emergency rooms or satellite labs.”
QIAsphere connectivity is possible by connecting the QIAsphere Base (Qbase), a small connectivity hub, to QIAstat-Dx and other QIAGEN platforms in minimal time through hospitals LAN or Wifi network, keeping sensitive patients data within the hospital network. The Qbase connectivity hub along with QIAsphere App will enable real-time monitoring across all customers QIAstat-Dx analyzers.
For more information on QIAsphere please visit https://www.qiagen.com/clp/qiasphere.
Further information on QIAGEN’s response to the coronavirus outbreak can be found here.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).